Active and passive immunotherapy for neurodegenerative disorders
about
AAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease.Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's diseaseStructural Correlates of Antibodies Associated with Acute Reversal of Amyloid -related Behavioral Deficits in a Mouse Model of Alzheimer DiseaseYokukansan inhibits neuronal death during ER stress by regulating the unfolded protein responseA cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaquesIntracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 miceAllele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosisRobust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapyWhite matter changes in dementia: role of impaired drainage of interstitial fluid.Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Beneficial catalytic immunity to abeta peptide.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody librariesImmunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the Igg1-skewed isotype distributionSoluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cellsSystemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD miceAmyloid-beta immunotherapy for Alzheimer's diseaseCNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic miceScanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearancePrion protein-specific antibodies-development, modes of action and therapeutics applicationAmyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.Amyloid-ß-directed immunotherapy for Alzheimer's disease.Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimagingCurrent and future treatments for Alzheimer's diseasePassive (amyloid-β) immunotherapy attenuates monoaminergic axonal degeneration in the AβPPswe/PS1dE9 mice.Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathologyClearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease.Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonistThe toxicity of tau in Alzheimer disease: turnover, targets and potential therapeuticsWheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD miceAlzheimer's disease: pathological mechanisms and recent insights.The many faces of tauCould immunomodulation be used to prevent prion diseases?
P2860
Q27318148-BFF64F7A-3E0C-4454-B4A4-3AB0E638EB1EQ27349010-E1F94DAE-AC79-49D4-A5E0-4C8BF3571CF9Q27658233-A50BA6D7-62FE-447A-B4E4-B2346C20CD84Q28475740-BD60BEF2-534E-4014-9FC1-210AB225ACF6Q28740910-A9EF4CBB-CA1B-4831-B272-E249EE4C06FFQ30486176-DC81FC83-F4D2-490F-A50C-D9517F099FE8Q30493543-CC83A058-3B58-4929-B27D-979F55E40068Q30497751-53254190-5EDC-4810-AA3C-D95787E38493Q30499456-6B54C9A0-CF1B-4ABB-B206-9D2047818EF1Q30880445-FC8E2CB7-6B2B-4149-9ED1-CC6F18DBAFFFQ33392254-C881AA76-BDE8-4436-AB83-5320BD7DE45AQ33549900-70B390B7-7208-4E56-ADE6-14952661B0A1Q33572338-CDEB51AD-160A-48A7-B6C9-94E8518B7105Q33573668-945216CE-16A7-455A-8ADE-1EDF6C76DD7DQ33639513-D28E9AF5-DD55-4E73-8728-7348193899EBQ33742312-CE8C4C21-FC1E-4D7B-A070-FC11DAB507C2Q33831036-41AFFB2F-6745-42BA-B1DF-4BB113A2C73AQ33863420-5BF519F5-D5FE-4BD6-9C30-E9BF9949AA37Q33926242-80027B8A-21F1-48DC-A65F-F74919A20F5FQ33954737-1D4EFA86-D847-443B-A8EA-7D90775EE537Q34017180-D8711F77-F5E4-43D2-9615-DDB3186EDF39Q34043432-81EF73B4-6BF1-49CC-B38F-A44AD0BABBA1Q34091134-D248937A-D5AF-48B7-83FA-763BF16F5951Q34348316-C173725A-92D6-4E3E-A1E4-562457A3CE8FQ34383525-DCB34462-D7A6-40E0-96CE-C22A47FF2D40Q34423386-38FA25B7-325B-46A3-83BF-D404D7F0BA51Q34543713-AB9EB857-6A9E-47E5-860F-069392660138Q34548700-E939FA42-A173-4E3C-A479-B2D41D7877B9Q34611770-BE333482-04F9-4565-BE8D-C8A8CCB7611BQ34646921-28625209-9B3C-4DA8-A8B0-04AD33743450Q34717836-528BB94B-4DA7-4F75-8B76-78E4D4D1D695Q34943311-3AE0ADD3-A0B9-40A0-A337-63E6516C4520Q34960461-902B21E3-EF5B-4091-B558-FF34FB9F2B36Q35050837-28952563-42CE-40E2-8C93-3407411631C5Q35137114-F980F948-3894-41E2-970E-53013A36B096Q35216140-251A4FC7-0CC9-4994-AA1E-5E863B9D3C38Q35300928-8CB57618-E04F-4982-B707-AA0E076361B3Q35687044-968A8DE4-DDDA-4949-9F0E-7BD9E6640116Q35870359-A3B96BF2-42A2-43C4-8DE2-664AC98A1308Q35875915-5FD395DC-DEC4-4A66-B792-6A54E543DBF9
P2860
Active and passive immunotherapy for neurodegenerative disorders
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Active and passive immunotherapy for neurodegenerative disorders
@ast
Active and passive immunotherapy for neurodegenerative disorders
@en
Active and passive immunotherapy for neurodegenerative disorders
@nl
type
label
Active and passive immunotherapy for neurodegenerative disorders
@ast
Active and passive immunotherapy for neurodegenerative disorders
@en
Active and passive immunotherapy for neurodegenerative disorders
@nl
prefLabel
Active and passive immunotherapy for neurodegenerative disorders
@ast
Active and passive immunotherapy for neurodegenerative disorders
@en
Active and passive immunotherapy for neurodegenerative disorders
@nl
P2860
P3181
P1476
Active and passive immunotherapy for neurodegenerative disorders
@en
P2093
David L Brody
P2860
P304
P3181
P356
10.1146/ANNUREV.NEURO.31.060407.125529
P407
P577
2008-01-01T00:00:00Z